On March 20, 2026, the FDA approved Opdivo (nivolumab) in combination with doxorubicin, vinblastine, and dacarbazine (AVD) for adult and pediatric patients 12 years and older with previously untreated Stage III or IV classical Hodgkin lymphoma (cHL) 5 The FDA approval was based on the Phase 3 SWOG 1826 study, which demonstrated a 58% reduction in the risk of disease progression or death (Hazard Ratio 0.42) 2 4 The SWOG 1826 study showed statistically significant improvement in progression-free survival for patients receiving Opdivo plus AVD compared with the standard of care BV-AVD 2 After a median follow-up of 36.7 months, the median overall survival had not been reached in either treatment arm, with only 9 deaths (1.8%) in the Opdivo plus AVD arm versus 17 deaths (3.4%) in the BV plus AVD arm 2 This represents the first immunotherapy combination approved in the U.S. for previously untreated advanced classical Hodgkin lymphoma in adults and pediatric patients ages 12 and older...
- Get link
- X
- Other Apps